Angiodynamics Inc (NASDAQ:ANGO) Short Interest Decreased By 1.32%

May 16, 2018 - By Ann Prendergast

AngioDynamics, Inc. (NASDAQ:ANGO) Logo

Investors sentiment increased to 1.26 in Q4 2017. Its up 0.09, from 1.17 in 2017Q3. It increased, as 14 investors sold AngioDynamics, Inc. shares while 48 reduced holdings. 22 funds opened positions while 56 raised stakes. 33.90 million shares or 1.62% more from 33.36 million shares in 2017Q3 were reported.
Goldman Sachs Grp has 119,330 shares for 0% of their portfolio. 21,313 are held by Bnp Paribas Arbitrage. Laurion Cap Limited Partnership holds 0% or 18,300 shares. Macquarie Group Inc Incorporated Ltd has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 54,769 shares. Nordea Mgmt invested in 144,043 shares or 0.01% of the stock. Moreover, First Quadrant L P Ca has 0.01% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Arizona State Retirement Sys holds 0.01% or 61,711 shares. State Street has 970,092 shares. Kennedy Mgmt holds 0.04% in AngioDynamics, Inc. (NASDAQ:ANGO) or 122,805 shares. Louisiana State Employees Retirement Sys has 0.01% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 15,800 shares. Campbell Company Invest Adviser Llc invested in 14,028 shares. Thomson Horstmann And Bryant holds 0.81% in AngioDynamics, Inc. (NASDAQ:ANGO) or 369,308 shares. Legal & General Grp Public Limited Liability Company owns 66,850 shares for 0% of their portfolio. Bancorporation Of Montreal Can reported 59,032 shares stake. Cap Fund Management, France-based fund reported 10,900 shares.

The stock of Angiodynamics Inc (NASDAQ:ANGO) registered a decrease of 1.32% in short interest. ANGO’s total short interest was 1.89 million shares in May as published by FINRA. Its down 1.32% from 1.92M shares, reported previously. With 164,600 shares average volume, it will take short sellers 12 days to cover their ANGO’s short positions. The short interest to Angiodynamics Inc’s float is 5.21%.

The stock increased 0.71% or $0.14 during the last trading session, reaching $19.87. About 55,511 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has declined 2.41% since May 16, 2017 and is downtrending. It has underperformed by 13.96% the S&P500.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $731.31 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 551.94 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 3 analysts covering Angiodynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. Angiodynamics had 5 analyst reports since January 5, 2018 according to SRatingsIntel. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Hold” rating given on Thursday, January 4 by Canaccord Genuity. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Monday, April 2. The stock has “Outperform” rating by Raymond James on Tuesday, April 3. The firm earned “Hold” rating on Thursday, March 29 by Canaccord Genuity. Craig Hallum downgraded AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, January 5 to “Hold” rating.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: